Moderna has turned into one of the market’s biggest movers this year, and the question now is whether the cash flows behind the business are strong and durable enough to support where the stock trades today. After such a sharp repricing on the back of vaccine headlines and pipeline updates, the issue for you is how that share price lines up with the cash Moderna is expected to generate over time.
- Over the past year, Moderna has delivered an 896.4% return, which puts a lot of future cash flow expectations under the spotlight for anyone looking at the current valuation.
- Recent approvals and clinical progress across Covid, flu and oncology programs can influence how quickly Moderna converts its research spend into future revenue streams and, ultimately, free cash generation.
- What if you looked at Moderna through its sales instead? See what Moderna's 39.9x P/S says about the price.
The stock's next move may depend on whether the current market price looks aligned with what Moderna's cash flows imply when run through a Discounted Cash Flow (DCF) lens.
If you want context for Moderna's huge move and its cash flow story, it helps to compare it with other high quality value ideas using the 32 high quality undervalued stocks
Is Moderna Getting Expensive on Cash Flow?
The Discounted Cash Flow (DCF) model here focuses on what Moderna can earn for shareholders over time, not just what it reports in any single quarter. Over the last twelve months the business recorded free cash outflow of about $2.2b, which means the model is leaning heavily on a shift from investment mode to future cash generation rather than on current profitability.
Analysts feeding this DCF expect Moderna’s free cash flow to move from losses to positive territory and then grow, so the model effectively assumes a recovering and then expanding cash profile. With that setup, the projections put Moderna's estimated intrinsic value modestly below the current share price of $248.69, suggesting today's market quote already reflects a fair amount of that improvement. Because Health Canada has approved Moderna's mRNA flu and combined flu Covid vaccines for adults 50+, the strong product pipeline helps explain why investors are comfortable paying above what the cash flows alone support right now. Find out what Moderna could be worth using our Discounted Cash Flow (DCF) estimate.
The Moderna Narrative: What Would Justify Today's Price?
Moderna’s Simply Wall St Narratives pick up exactly where the DCF puzzle leaves you. They spell out which paths for growth, profitability and earnings would need to play out for the stock to be worth materially more or less than it is today on the market, and they sit on the Community page. Each narrative links its number to a clear view on how Moderna's expansion prospects, margin profile and risk picture might evolve, which you can come back to as fresh information arrives.
Bullish and bearish Narratives on Moderna are both anchored in the mRNA platform, yet they split on how much future oncology and rare disease success to factor in.
Bull case: 8% undervalued
The bullish analyst Narrative on Simply Wall St frames Moderna as a broader mRNA platform story, not just a Covid vaccine business.
"The positive Phase 3 results for Intismeran in adjuvant melanoma, combined with nine ongoing Phase 2 and Phase 3 trials across multiple settings, open a path for Moderna to build a broader immuno oncology franchise…"
Discover why this Narrative puts Moderna at 8% undervalued.
Bear case: 71% overvalued
The analyst consensus Narrative on Simply Wall St focuses on how much future cancer and rare disease revenue is already assumed in the current Moderna price.
"The current valuation, including a market cap around US$70b and a forward P/S of 36.8x cited by some bearish brokers, implies Moderna’s cancer and rare disease franchises will achieve very broad adoption and significant long-duration revenue that critics argue is already priced into the share price…"
Explore why this Narrative puts Moderna at 71% overvalued.
One more angle on Moderna that could change your view
Before you stop at the cash flow story, it is worth knowing that Simply Wall St’s broader checks have already flagged specific areas of concern that you may want to weigh for yourself. Take a closer look at 1 major warning sign before settling on a valuation.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com